晚期前列腺癌联合放射性药物治疗与免疫治疗的肿瘤内在血液与影像相关标志物
PRINCE试验显示177Lu-PSMA-617联合帕博利珠单抗对转移性去势抵抗性前列腺癌有临床活性。本研究对37例受试者在基线、治疗12周和疾病进展时进行ctDNA、CTC和PET影像分析,发现低基线ctDNA分数和高PSMA亲和力与更优疗效相关,TP53/RB1/PTEN改变与更高18F-FDG亲和力和更差预后相关。
要点
- 低基线ctDNA分数和高PSMA亲和力与更优治疗反应相关,可能具有复合生物标志物价值。
- TP53、RB1或PTEN抑癌基因改变与更高18F-FDG亲和力、代谢肿瘤体积和更差预后相关。
- 治疗12周时ctDNA检测和PSMA PET均是反应深度和持久性的强指标。
核心结论
- 首次提供前列腺癌联合放射性药物治疗与免疫治疗反应和耐药决定因素的综合分子与影像学见解。
- 提出生物标志物策略以指导未来临床开发。
研究设计与样本
- 对PRINCE试验中37例受试者在基线、治疗12周和疾病进展时进行ctDNA、CTC和PET影像分析。
- ctDNA靶向测序覆盖70余个前列腺癌基因,CTC在EpicSciences平台计数并结合选择性单细胞全基因组测序。
- PET影像包括连续PSMA PET以及基线18F-FDG PET。
主要发现
- 低基线ctDNA分数和高转移灶PSMA亲和力与更优治疗反应相关,可能具有复合生物标志物价值。
- TP53、RB1或PTEN抑癌基因改变与更高18F-FDG亲和力和18F-FDG PET代谢肿瘤体积以及更差预后相关。
- 治疗12周时ctDNA检测和PSMA PET影像均是反应深度和持久性的强指标。
- 疾病进展时PET影像PSMA表达较基线降低,并得到ctDNA和CTC拷贝数谱亚克隆重塑及抑癌基因突变克隆扩增的支持。
临床怎么用
- 基线ctDNA分数和PSMA亲和力可能用于筛选联合治疗的潜在获益患者。
- 治疗12周ctDNA检测和PSMA PET可用于监测反应深度和持久性。
- TP53、RB1或PTEN改变伴高18F-FDG亲和力提示更差预后,可能需强化监测。
局限性
- 样本量有限(n=37),结论需更大规模研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The PRINCE trial showed the clinical activity for 177Lu-PSMA-617 in combination with pembrolizumab for metastatic castration-resistant prostate cancer. To refine patient selection and improve response monitoring strategies to this combination, we investigated candidate tumor-intrinsic biomarkers of treatment response and resistance. Methods: We performed circulating tumor DNA (ctDNA), circulating tumor cell (CTC), and PET imaging analyses at baseline, 12 wk on-treatment, and disease progression in participants enrolled in PRINCE (n = 37). We performed targeted sequencing for ctDNA quantification and genomic analysis of more than 70 prostate cancer genes. CTC enumeration was performed on the EpicSciences platform and was combined with selective single-cell whole-genome sequencing. PET imaging included serial PSMA PET as well as 18F-FDG PET imaging at baseline. Results: A low baseline ctDNA fraction and high PSMA avidity in metastatic lesions were linked to superior treatment responses and may have composite biomarker value. Genomic alterations in tumor suppressor genes TP53, RB1, or PTEN were associated with higher 18F-FDG avidity and metabolic tumor volume on 18F-FDG PET imaging and worse prognosis. At 12-wk on-treatment, both ctDNA detection and PSMA PET imaging were strong indicators of response depth and durability. At disease progression, PSMA expression on PET imaging was lower compared with baseline and supported by subclonal remodeling of ctDNA and CTC copy number profiles and by clonal expansions of tumor suppressor gene mutations. Conclusion: We provide the first integrated molecular and imaging insights into determinants of response and resistance to combined radiopharmaceutical therapy and immunotherapy in prostate cancer and propose biomarker strategies to inform future clinical development.
引用
- Tolmeijer SH, Kwan EM, Gafita A, et al. Tumor-Intrinsic Blood and Imaging Correlatives in Advanced Prostate Cancer Treated with Combination Radiopharmaceutical Therapy and Immunotherapy. J Nucl Med. 2026. PMID: 42722442. doi:10.2967/jnumed.126.273266
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。